

9 July 2009

Proposal to fund zuclopenthixol (Clopixol) tablets

PHARMAC is seeking feedback on a proposal to fund a tablet form of the antipsychotic zuclopenthixol (Clopixol), through a provisional agreement with Lundbeck Australia Pty Ltd. A depot injection form of Clopixol is already funded.

Key aspects of the proposal are as follows:

- From 1 September 2009 zuclopenthixol hydrochloride 10 mg tablets would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at a price and subsidy of \$31.45 per 100 tablets (ex-manufacturer, excluding GST).
- A rebate arrangement would apply to Clopixol tablets.

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Thursday 23 July 2009** to:

Geraldine MacGibbon
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: geraldine.macgibbon@pharmac.govt.nz

Fax: (04) 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.